Title: Follow-on biologics
Subtitle: hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007.
Subjects: Government policy, Drug development, Pharmaceutical technology, Pharmaceutical biotechnology, Patents
Places: United States